- NanoString Technologies ( NASDAQ: NSTG ) and Abcam ( NASDAQ: ABCM ) said they expanded their collaboration to advance spatial multiomics research.
- Under the agreement, the companies will co-market Abcam antibodies for NanoString's high-plex spatial multiomic solutions.
- Abcam RabMAb recombinant antibodies will be commercialized as part of the first 64-plex protein panel for NanoString's CosMx Spatial Molecular Imager (SMI).
- "This relationship will further expand the depth and breadth of spatial biology offerings on NanoString instrumentation into new frontiers of human biology down to single-cell resolution— a true revolution in the spatial biology field," said NanoString President and CEO Brad Gray.
- NSTG +4.50% to $6.50 premarket Nov. 9
- ABCM -1.73% to $14.77 premarket
For further details see:
NanoString, Abcam team up to advance spatial multiomics research